From microdose to high dose — a science-backed breakdown of THC amounts by experience level, consumption method, onset time and duration.
THC dosing is one of the most discussed and most misunderstood topics in cannabis use. Unlike pharmaceutical drugs with standardised dosing protocols, cannabis produces highly variable effects depending on a complex matrix of individual factors, consumption method, product chemistry and set and setting. Two people consuming the same amount of the same product in the same room can have dramatically different experiences — one may feel pleasantly relaxed, the other overwhelmed and anxious.
This variability arises from several interacting biological factors. endocannabinoid system (ECS) baseline tone — the natural density and sensitivity of CB1 receptors — differs between individuals and is influenced by genetics, lifestyle, prior cannabis exposure and even diet. People with naturally higher ECS tone tend to experience milder effects from equivalent doses; those with lower baseline ECS activity may be significantly more sensitive to THC.
Body weight and composition play a supporting role: larger body mass generally requires higher doses to achieve equivalent plasma concentrations, though the relationship is not linear due to THC’s fat-storage pharmacokinetics. Prior cannabis exposure (tolerance) is one of the most powerful modifiers — a daily consumer may need 10 times the dose of a naive user to achieve the same effect intensity.
Cannabis metabolism is also genetically influenced. CYP2C9 enzyme variants determine how quickly THC is converted to 11-OH-THC and subsequently to inactive metabolites. Poor metabolisers experience stronger, longer-lasting effects from equivalent doses; ultra-rapid metabolisers may find standard doses underwhelming. This pharmacogenomic variability is a key reason why personalised cannabis dosing guidance must always start conservatively.
A practical dose framework was popularised by Project CBD and has been widely adopted by clinicians and cannabis educators. It divides THC exposure into four functional tiers based on milligram amounts, each corresponding to a distinct effect profile.
| Dose Tier | THC Amount | Expected Effects | Best For |
|---|---|---|---|
| Microdose | 1–2.5 mg | Mood lift, mild stress relief, no intoxication | New users, daytime function, productivity |
| Low | 2.5–15 mg | Relaxation, mild euphoria, possible anxiety at upper range in naive users | Beginners, pain relief, mild sleep support |
| Moderate | 15–30 mg | Clearly psychoactive, time distortion, strong relaxation or euphoria | Experienced consumers, deeper sleep, nausea/appetite stimulation |
| High | 30–50 mg | Intense psychoactivity, potential dissociation, strong sedation | High-tolerance consumers, specific medical indications |
| Very High | 50 mg+ | Extreme intoxication, high anxiety/panic risk in most users | Only very high-tolerance experienced patients |
These ranges assume oral (edible or tincture) dosing, where the milligram figure on the label corresponds directly to the dose consumed. Inhalation dosing is inherently less precise because THC delivery depends on inhalation depth, hold time, product potency and device efficiency. A puff from a 20% THC joint delivers an estimated 2–4 mg THC to a casual inhalation; a deep lungful hold from a concentrate vape can deliver 15–30 mg in a single breath.
Inhalation delivers THC to the bloodstream via the pulmonary capillaries in the lungs, bypassing hepatic first-pass metabolism. Onset is rapid — typically 5–15 minutes to peak effect — and duration is relatively short, 1–3 hours. This makes inhalation the most titratable consumption method: effects appear quickly enough to allow real-time dose adjustment between inhalations.
For flower with a known THC percentage, a rough calculation estimates the THC per gram at 10× the percentage (e.g., 20% THC = approximately 200 mg/g). The efficiency of inhalation — the proportion of available THC that actually reaches the bloodstream — varies by method: smoking is estimated at 20–35% bioavailability; vaping at 45–70%; direct dabbing of concentrates at up to 80%. Applying a 30% bioavailability factor to a single 0.3g inhalation from 20% THC flower gives approximately 18 mg delivered, though actual user dose will be a fraction of this based on inhalation technique.
For practical dosing by inhalation, the most reliable approach is the "one puff and wait" method: take a single inhalation, set the cannabis down, and assess effects at the 15-minute mark. If the desired effect has not been achieved, take one more inhalation and repeat the assessment. This prevents the common experience of over-inhalation during a session, where the cumulative dose is only apparent when peak effects arrive.
Edible cannabis pharmacokinetics represent a completely different pharmacological challenge compared to inhalation. When THC is consumed orally — whether in a gummy, chocolate, capsule, beverage or infused food — it passes through the gastrointestinal tract and undergoes first-pass metabolism in the liver before entering systemic circulation. This metabolic step converts delta-9-THC into 11-hydroxy-THC at a much higher proportion than inhalation, and 11-OH-THC is believed to cross the blood-brain barrier more readily and produce longer-lasting, qualitatively more intense effects.
The onset of edible effects is notoriously variable, ranging from 30 minutes to over 2 hours depending on gastric emptying rate, fed versus fasted state, individual metabolic speed and lipid content of the food matrix. Consuming an edible with fatty food accelerates THC absorption; consuming on an empty stomach produces a faster but often more intense and unpredictable onset.
The most dangerous dosing error with edibles is redosing before the first dose has reached peak effect. A person consuming 10 mg who feels nothing at 60 minutes may consume another 10 mg — and then experience the combined 20 mg effect 30–90 minutes later as both doses converge on the bloodstream simultaneously. This is one of the most common causes of cannabis-related emergency room visits in legalised jurisdictions.
| Consumption Method | Onset | Peak | Duration | Bioavailability |
|---|---|---|---|---|
| Smoking (joint/pipe) | 5–10 min | 20–30 min | 1–3 hours | 20–35% |
| Dry herb vaping | 5–10 min | 15–25 min | 1–2.5 hours | 45–70% |
| Oil vape cartridge | 5–15 min | 20–30 min | 1–2 hours | 40–60% |
| Edible (oral) | 30–120 min | 1–3 hours | 4–8 hours | 4–20% |
| Sublingual tincture | 15–45 min | 45–90 min | 2–4 hours | 20–35% |
| Concentrate (dab) | 2–5 min | 10–20 min | 1–2 hours | 70–85% |
Cannabis tolerance develops through CB1 receptor downregulation — the brain’s adaptive response to repeated THC exposure. As CB1 receptors in the prefrontal cortex, hippocampus and striatum are repeatedly activated by THC, the system compensates by reducing receptor density (downregulation) and receptor sensitivity (desensitisation). This means that a dose which previously produced strong effects gradually becomes insufficient to produce the same response.
Tolerance develops at different rates in different brain regions and for different effects. Euphoric and psychomotor impairment effects build tolerance quickly — often within days of daily use. Anti-nausea and appetite-stimulating effects may show slower tolerance development. Analgesic effects occupy a middle ground, with some medical patients maintaining effectiveness at stable doses over months.
For practical dosing management, the concept of a tolerance break (T-break) is well-established. Even 48–72 hours of abstinence can reduce acute tolerance meaningfully. A 2-week T-break restores significant receptor sensitivity; a 30-day break returns CB1 receptor density close to pre-cannabis-exposure baseline, as demonstrated by PET imaging studies. After a T-break, re-introduction at the previous dose often produces effects far exceeding expectations — recalibrating back to a lower dose is essential post-T-break.
Clinical dose-ranging studies for THC have been conducted primarily in the context of specific medical applications. A pivotal dose-finding study for nabilone (synthetic THC) in chemotherapy-induced nausea found that 1–2 mg twice daily was effective with manageable side effects; higher doses produced increasing anxiety and dysphoria without proportional benefit in most patients.
In chronic pain research, a 2010 Canadian study published in CMAJ found that smoked cannabis at 9.4% THC (approximately 25 mg flower per administration) significantly reduced pain intensity compared to placebo in patients with refractory neuropathic pain. The medium 9.4% dose was more effective than the 6% dose but comparable to the 12% dose, supporting a plateau effect in analgesic response.
Sleep research using oral THC consistently finds dose-dependent effects: low doses (5–10 mg) reduce sleep onset latency and increase time in stage 3 deep sleep; higher doses (15–25 mg+) begin to suppress REM sleep, which can impair memory consolidation and produce vivid dreaming upon cessation. Long-term nightly high-dose use is associated with REM rebound (intense dreaming) when stopping, which is a symptom of THC dependence.
Anxiety research presents a clear biphasic dose-response pattern: low doses of THC (1–5 mg) demonstrate anxiolytic properties in clinical models, while higher doses (10+ mg) reliably increase anxiety in a significant proportion of subjects, particularly those naive to cannabis or genetically predisposed to anxiety disorders. This biphasic relationship is fundamental to the "less is more" principle in cannabis dosing for anxiety-prone individuals.
Cannabis cannot cause a lethal overdose through direct pharmacological mechanisms — the brainstem, which controls cardiovascular and respiratory functions, has very few CB1 receptors compared to the cortex and limbic system. However, excessive THC intake can cause a deeply unpleasant acute experience including severe anxiety, paranoia, rapid heart rate, nausea and vomiting, dissociation and, in rare cases, cannabis hyperemesis syndrome (CHS) in chronic heavy users.
If you or someone else consumes too much THC, the evidence-backed interventions include: moving to a calm, familiar, safe environment; having a trusted companion present; consuming CBD (which partially antagonises CB1 receptor activation and reduces anxiety); eating food and drinking water; and, if severe anxiety persists, seeking medical attention. Black pepper (chewed or inhaled) is a widely reported anecdotal remedy that may work through caryophyllene’s action at CB2 receptors, reducing anxiety without CB1 blockade.
Cannabis-induced anxiety and paranoia typically resolve within 2–3 hours for smoked/vaped doses and within 4–8 hours for edibles without medical intervention. Knowing this timeline can be grounding during an overwhelming experience: the effects are temporary, time-limited, and non-lethal. Emergency rooms in legal cannabis states report the majority of cannabis-related visits are anxiety and panic events — unpleasant but medically uncritical.
A microdose is 1–2.5 mg of THC. At this level most people experience subtle mood enhancement and mild stress reduction without perceptible intoxication. It is ideal for functional daytime use and for new consumers building tolerance gradually.
First-time users should start with 1–2.5 mg for edibles, or a single small inhalation of low-potency flower (under 15% THC). Wait 2 full hours before redosing edibles. Most negative first experiences result from taking too much too quickly, especially with edibles.
Oral THC is metabolised by the liver into 11-hydroxy-THC, a more potent compound than delta-9-THC. This produces more intense, longer-lasting effects at equivalent milligram doses. Edible onset is also unpredictable (30 min to 2+ hours), making accidental overdosing common.
Inhalation produces effects for 1–3 hours. Edibles typically last 4–8 hours, sometimes longer at high doses. Tinctures taken sublingually last 2–4 hours. Tolerance, body weight and individual metabolism significantly affect duration.